June was a Tough Month for European Biotech… #Fail

06/07/2016 - 3 minutes

Abivax, Celyad, Circassia and Genticel – these are all European Biotechs that took a hit after failing key clinical trials in June. How are they doing now?

Four different public Biotechs suffered setbacks in some of their advanced clinical trials. And, as always, the words ‘failed to meet primary endpoint‘ weren’t very popular with investors…

One of them was Toulouse-based Genticel. This Biotech had already suffered a major drop back in January, when their Phase II results for HPV infection failed to meet the primary endpoint in the middle of the trial.

The company had been slowly recuperating, even publishing some promising news in early June. But the final results of the HPV trial soon sent the stock price down by 70%. Hard times indeed…

Abivax is another French antiviral Biotech that didn’t have it easy. Its frontrunner candidate for Hepatitis B (which was 2 years ahead of competition) has received a tough sentence –

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

You might also be interested in the following:


Support Us

Become a Member